|
Miyazawa K, Kondo Y, Nakano M, Esteve-Pastor MA, Rivera-Caravaca JM, Senoo K, Kobayashi Y, Lip GYH. Risk factors for the development of incident atrial fibrillation in patients with cardiac implantable electronic devices. Eur J Intern Med. 2018 Jun;52:54-59. doi: 10.1016/j.ejim.2018.02.019. Epub 2018 Mar 2. PubMed PMID: 29490874.
AÑO: 2018; IF: 3.66
|
29490874
|
Esteve-Pastor MA, Rivera-Caravaca JM, Roldán V, Vicente V, Romiti GF, Romanazzi I, Proietti M, Valdés M, Marín F, Lip GYH. Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in 'real-world' atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients. Int J Cardiol. 2018 Mar 1;254:125-131. doi: 10.1016/j.ijcard.2017.11.087. Epub 2017 Dec 14. PubMed PMID: 29248163.
AÑO: 2018; IF: 3.471
|
|
Esteve-Pastor MA, Orenes-Piñero E, Roldán V, Lacunza-Ruiz J, Valdés M, Marín F. Intra-ventricular thrombus resolution after anticoagulation therapy with rivaroxaban in patient with poor anticoagulation quality. Cardiol J. 2018;25(1):151-154. doi: 10.5603/CJ.2018.0014. PubMed PMID: 29512103.
AÑO: 2018; IF: 1.743
|
|
Pastori D, Rivera-Caravaca JM, Esteve-Pastor MA, Roldán V, Marín F, Pignatelli P, Violi F, Lip GYH. Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients. Circ J. 2018 Apr 25;82(5):1286-1292. doi: 10.1253/circj.CJ-17-1318. Epub 2018 Mar 16. PubMed PMID: 29553090.
AÑO: 2018; IF: 3.025
|
|
Esteve-Pastor MA, Rivera-Caravaca JM, Roldán-Rabadán I, Roldán V, Muñiz J, Raña-Míguez P, Ruiz-Ortiz M, Cequier Á, Bertomeu-Martínez V, Badimón L, Anguita M, Lip GYH, Marín F; FANTASIIA Investigators. Quality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry. Europace. 2018 Sep 1;20(9):1435-1441. doi: 10.1093/europace/eux314. PubMed PMID: 29095971.
AÑO: 2018; IF: 6.1
|